Navigation Links
Is extra-corporal liver support with prometheus safe in patients with end-stage liver disease?
Date:5/20/2008

Patients with end-stage liver disease would benefit from liver supportive liver therapy while waiting for stabilization of hepatic functions or to enable bridging to liver transplantation. Albumin dialysis improves patients' general condition, including cardiovascular and renal function as well as the degree of hepatic encephalopathy. Studies evaluating the hemodynamic alterations in stable patients with cirrhosis during extra-corporal intervention remain scarce, though such knowledge might evidently improve patient safety and perhaps lessen reluctance toward the early use of extra-corporal liver support.

The decision to use extra-corporal liver support in the treatment of patients with end-stage liver disease hinges on many factors, with safety considerations a major concern. The choice of treatment will depend on the risk of adverse events, and possible positive or negative hemodynamic influences between the available treatment modalities.

A research article to be published on April 7, 2008 in the World Journal of Gastroenterology addresses these issues. In this clinical study, the authors aimed to determine the hemodynamic profile of intervention with Prometheus, using MARS and hemodialysis as control groups, in patients with end-stage liver disease. They found the Prometheus system does not aggravate the systemic hemodynamics. However, Prometheus therapy does not exert an equally beneficial influence on arterial pressure as seen during MARS treatment. It was concluded that an intervention using extra-corporal liver support with albumin-dialysis should not be withheld merely because of safety considerations in the future.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Advanced Age No Bar to Liver Transplant
2. Researchers Find Better Way to Deliver Blood Thinner
3. Federal research plan to determine nanotech risks fails to deliver
4. Liver cancer marker could yield blood test for early detection
5. Blood Marker Might Help Spot Early Liver Cancer
6. Natural Protein Could Help Spot, Treat Liver Cancer
7. Diet Change Can Curb Fatty Liver Disease
8. US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
9. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
10. Re-plumbing liver helps beat cancer
11. Free Prescription Drug Program Uses Internet to Deliver Cards - Offers Assistance to Uninsured
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Mother Nature isn’t the only mom ... fruits and vegetables. , Celebrate these women with more than just a bouquet ... with these five garden-themed options. , Vibrant, Edible, Compact Plants from BrazelBerries: , ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... to identify, fund and implement ideas aimed at improving care and reducing readmission ... “Part of our vision for Trinity Health is to drive innovation that transforms ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and Vancouver, WA, has announced the latest beneficiary of their ongoing community ... and their Mammography Program, which provides free mammograms and diagnostic breast care ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Multiple Myeloma Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Multiple Myeloma market valuations and forecast, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
Breaking Medicine Technology: